Market Overview

Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe


, french MedTech start up, leads the new booming
category of Digital therapeutics with its revolutionary « at home «
neurofeedback, to train the brain and cure neuropsy disorders without
Co-founder INRIA-IT2,
existing shareholders and now HARA,
which are business angels experts in medical device category, joined
this fund raise. BPI
de Rennes
is also part of this tour.

Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in
Rennes are computing real time signaling softwares. The neurofeedback
technique is non invasive, at home and without drugs. MENSIA
treats ADHD, Attention Deficit Disorders with or without
Hyperactivity, children and adolescents. This unique medical device is a
therapeutic video game on an interactive tablet connected to the brain
activity. Children learn to control their attention by exercising 3
times a week during 4 months of treatment. Visual feedback given during
the game, allows the children to learn, control and create automatisms.
Six years of R&D with 12 $millions invested, including the last largest
clinical multicentric trial never ever made, NEWROFEED-Koala,
successfuly lead to the grant of a CE mark class IIa in Europe. Kick
start of the sales in March for France.
37 health points of care
from french national partner HOMEPERF,
delivers family training for home use of Koala. The device is prescribed
and ordered directly on the website. Family received their Mensia Koala
at home : all items ready to use for 4 month treatment, with webportail
supervision. Children benefit from significant reduction of their
attention deficit and or hyperactivity with long lasting effects.
Benefit/Risk ratio is extremely favorable and no adverse event compared
to the amphetamines drugs (Ritaline).

du Peloux
, CEO of Mensia Technologies : « We are proud to deliver
the first worldwide digital therapeutic device to treat ADHD with a
Class IIa registration for medical scripts and follow up all over
Europe. Far from neurogaming, we have 5 patents, randomised clinical
trials and state of the art expertise in brain computer interface. Our
pipeline of « at
home neurofeedback
» is promising : resistant chronic low back pain
despite opiods, is our next medical device. Mensia Technologies
initiates now the next tour for a serie A of 20 M$ aiming to the USA

About Mensia Technologies :
Mensia Koala :,
clinical study :
BPI Rennes :

View Comments and Join the Discussion!